Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer

PURPOSE: NCCTG (North Central Cancer Treatment Group) N9831 is the only randomized phase III trial evaluating trastuzumab added sequentially or used concurrently with chemotherapy in resected stages I to III invasive human epidermal growth factor receptor 2–positive breast cancer. PATIENTS AND METHO...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Perez, Edith A., Suman, Vera J., Davidson, Nancy E., Gralow, Julie R., Kaufman, Peter A., Visscher, Daniel W., Chen, Beiyun, Ingle, James N., Dakhil, Shaker R., Zujewski, JoAnne, Moreno-Aspitia, Alvaro, Pisansky, Thomas M., Jenkins, Robert B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2011
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236650/
https://ncbi.nlm.nih.gov/pubmed/22042958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.7045
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia